mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial
Cailu Shen(Sun Yat-sen University), Yanhong Deng(Sun Yat-sen University), Zehua Wu(Shanghai Jiao Tong University), Guangjian Liu(Sun Yat-sen University), Xiaoyu Xie(Sun Yat-sen University), Jiayu Ling(Sun Yat-sen University), Yue Cai(Sun Yat-sen University), Lishuo Shi(Sun Yat-sen University), Meijin Huang(Sun Yat-sen University), Tenghui Ma(Sun Yat-sen University), Liang Kang(Sun Yat-sen University), Hui Wang(Henan Medical University), Jianwei Zhang(Capital Medical University), Yonghua Cai(Sun Yat-sen University), Xiaojian Wu(Guangxi Academy of Agricultural Science), Yan Huang(Shanghai Pulmonary Hospital), Huaiming Wang(Sun Yat-sen University), Shuangling Luo(Sun Yat-sen University), Huabin Hu(Sun Yat-sen University), Ping Lan(Sun Yat-sen University), Yunle Wan(Sun Yat-sen University), Zhiyang Zhou(Shanghai Jiao Tong University), Fangqian Li(Central South University)
Cited by 9
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2023|892
Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence
|Nature Medicine|2019|710
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456